Cipla's Goa Facility Awarded VAI Status Following US FDA Inspection

US FDA Classifies Cipla's Goa Facility as Voluntary Action Indicated

The US Food and Drug Administration (USFDA) has classified Cipla's Goa facility as Voluntary Action Indicated (VAI) following a recent inspection. This classification indicates that the USFDA will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time.

According to a regulatory filing from Cipla, the USFDA had inspected the company's Goa facility in April of this year. The inspection, which took place from April 6 to April 17, 2026, was a routine current Good Manufacturing Practices (cGMP) inspection along with a Pre-Approval Inspection (PAI) at the company's manufacturing facility in Verna, Goa.

The USFDA classified the inspection as VAI through a communication dated June 10, 2026. This classification means that will not face any immediate regulatory consequences as a result of the inspection findings.